Patrick Wood, an analyst from Morgan Stanley, maintained the Buy rating on RxSight (RXST – Research Report). The associated price target remains the same with $42.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Patrick Wood has given his Buy rating due to a combination of factors that, despite recent challenges, suggest potential for RxSight’s growth. Although the company faced a rough start to the year with a significant miss in Q1 sales and a downward revision of 2025 guidance, Wood notes that the placement numbers remain encouraging. The long-term demand for RxSight’s products, driven by the demographic of early retirees who are less sensitive to macroeconomic fluctuations, supports a positive outlook.
Despite the troubling drop in utilization rates, Wood believes that the company’s ability to maintain a strong LDD placement number indicates underlying strength. The revised guidance, while lower, still reflects a substantial year-over-year growth, which suggests that the company’s fundamentals remain intact. Wood’s analysis implies that while short-term trust may be challenged, the long-term prospects for RxSight justify a Buy rating.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $44.00 price target.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RXST in relation to earlier this year.